Abstract
Chronic hepatitis B virus (HBV) infection has a variable course leading to cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis and clinical outcome of HBV infection are strictly dependent on both viral factors, such as life cycle and genotypic variants, and host immune response (i.e. viral persistence). Although therapy of hepatitis B is evolving, which between single and/or combined agents are most effective, how long therapy should last, which criteria should be used to start or continue and switch or stop therapy are to be defined. Two major groups of therapies are currently utilized for chronic hepatitis: immunomodulatory (interferons) and antivirals (nucleoside and nucleotide analogues), all with their own advantages and limitations. In fact, the development of specific antiviral therapies has provoked the appearance of a relevant problem: drug resistances. The emerged antiviral drug-resistant strains of HBV leads to a poor prognosis for infected patients. Thus, many basic and clinical research challenges remain in defining optimal means of management of viral hepatitis B and its related liver diseases. This paper provides a review of new available and developing treatment options for HBV associated liver diseases. In the near future the most realistic therapeutic option for the majority of patients with HBV infection will be combination and/or long-term use of new and stronger antiviral drugs, if they maintain good safety profiles, achieve low resistance rates and will be available at lower prices.
Keywords: HBV, IFNs, nucleoside/nucleotide analogues, drug resistance, therapy, viral variants
Current Medicinal Chemistry
Title: Viral Hepatitis B: Established and Emerging Therapies
Volume: 15 Issue: 9
Author(s): Clara Balsano and Anna Alisi
Affiliation:
Keywords: HBV, IFNs, nucleoside/nucleotide analogues, drug resistance, therapy, viral variants
Abstract: Chronic hepatitis B virus (HBV) infection has a variable course leading to cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis and clinical outcome of HBV infection are strictly dependent on both viral factors, such as life cycle and genotypic variants, and host immune response (i.e. viral persistence). Although therapy of hepatitis B is evolving, which between single and/or combined agents are most effective, how long therapy should last, which criteria should be used to start or continue and switch or stop therapy are to be defined. Two major groups of therapies are currently utilized for chronic hepatitis: immunomodulatory (interferons) and antivirals (nucleoside and nucleotide analogues), all with their own advantages and limitations. In fact, the development of specific antiviral therapies has provoked the appearance of a relevant problem: drug resistances. The emerged antiviral drug-resistant strains of HBV leads to a poor prognosis for infected patients. Thus, many basic and clinical research challenges remain in defining optimal means of management of viral hepatitis B and its related liver diseases. This paper provides a review of new available and developing treatment options for HBV associated liver diseases. In the near future the most realistic therapeutic option for the majority of patients with HBV infection will be combination and/or long-term use of new and stronger antiviral drugs, if they maintain good safety profiles, achieve low resistance rates and will be available at lower prices.
Export Options
About this article
Cite this article as:
Balsano Clara and Alisi Anna, Viral Hepatitis B: Established and Emerging Therapies, Current Medicinal Chemistry 2008; 15 (9) . https://dx.doi.org/10.2174/092986708783955383
DOI https://dx.doi.org/10.2174/092986708783955383 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gamma-Tocotrienol Synergistically Promotes the Anti-proliferative and
Pro-apoptotic Effects of Etoposide on Breast Cancer Cell Lines
Current Molecular Pharmacology A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative
Current Drug Safety Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Current Protein & Peptide Science Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry Glutathione Transferases as Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Local Delivery of Therapeutics for Percutaneous Coronary Intervention
Current Drug Delivery Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Current Alzheimer Research Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Current Advances in Gene Therapy for the Treatment of Genodermatoses
Current Gene Therapy Eating Disorders in the Time of the COVID-19 Pandemic: A Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances in Fish Cytokine Biology Give Clues to the Evolution of a Complex Network
Current Pharmaceutical Design Gut Microbiota and Alcoholic Liver Disease
Reviews on Recent Clinical Trials Prediction and Identification of Krüppel-Like Transcription Factors by Machine Learning Method
Combinatorial Chemistry & High Throughput Screening Identification of Leads from Marine Seaweeds against Human β-tubulin
Letters in Drug Design & Discovery Natural Bioactive Compounds against Oxidative Stress: Dietary Polyphenols Strike Back
Endocrine, Metabolic & Immune Disorders - Drug Targets NF-κB as a Target for Modulating Inflammatory Responses
Current Pharmaceutical Design